$ cat ./records/gates-foundation-funds-pneumococcal-vaccine-introduction-across-g-2009.txt
Gates Foundation Funds Pneumococcal Vaccine Introduction Across Gavi-Eligible Countries
[RECORD.TXT] · cat --full
The Gates Foundation partnered with Gavi to negotiate dramatically reduced prices for pneumococcal conjugate vaccines (PCV) from Pfizer and GlaxoSmithKline and fund their introduction across low-income countries. Pneumonia was killing nearly 1 million children under five annually. The Advance Market Commitment structure — co-designed by Gates advisors — guaranteed manufacturers a subsidised price for the first 200 million doses, cutting the per-dose cost from $70 to approximately $3.50 for eligible countries and triggering the fastest vaccine introduction in GAVI history.
Source: https://www.gavi.org/investing-gavi/funding/donor-profiles/gates-foundation
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants $50 Million to PSI for Voluntary Male Circumcision in Southern Africa
Next →
Gates Foundation Funds Promotion of Orange-Fleshed Sweet Potato Across Sub-Saharan Africa to Fight Vitamin A Deficiency
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.